Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. Meta-analysis shows 57% mortality reduction.

With the ongoing COVID-19 pandemic continuing to spread to hundreds of thousands the world over, scientists are still seeking an effective treatment or vaccine. Now, a new study published on the preprint server medRxiv* in July 2020 reports that an older treatment modality, namely, the use of convalescent antibody-rich plasma, brings down the mortality rate in

Read More


Half of low-income communities have no ICU beds. Income Disparities In Covid-19 Access To Critical Care Services

Policies that facilitate hospital coordination are urgently needed to mitigate effects of the COVID-19 pandemic A new Penn Medicine study sheds light on yet another reason why the coronavirus pandemic is disproportionately killing the poor: Residents in low-income neighborhoods lack access to intensive care unit (ICU) beds. While the shortage of ICU beds in the

Read More


NIH will test synthetic monoclonal antibodies and other experimental therapeutics for mild and moderate COVID-19

Initial clinical trial to determine if monoclonal antibodies can shorten severity of COVID-19 in outpatients. Source NIH A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of

Read More


Singapore scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 & SARS patients, and in uninfected individuals

Singapore study shows that SARS-CoV-2-specific T cells are present in all recovered COVID-19 patients. These T cells were also found in all subjects who recovered from SARS 17 years ago, and in over 50% of both SARS-CoV-1 and SARS-CoV-2 uninfected individuals tested, suggesting that a level of pre-existing SARS-CoV-2 immunity is present in the general

Read More


COVID-19: UK Royal College of Pathologists on convalescent plasma effectiveness

High-quality research is essential in underpinning the clinical use of COVID-19 convalescent plasma and this article describes the UK randomised controlled trials underway. RATIONALE FOR USING CONVALESCENT PLASMA The global pandemic of the new coronavirus SARS-CoV-2 has not just medical, but also historical significance. In many parts of the world, the exponential epidemic curve of

Read More


Cord Blood T-Regulatory Cells Show Promise in COVID-19 Induced ARDS

Normally, regulatory T cells (also known as T regulatory cells or Tregs) migrate into inflamed tissues, dampening inflammatory responses and hastening tissue repair. Patients with coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) have protracted hospitalizations characterized by excessive systemic inflammation(cytokine storm) and delayed lung repair, which is partly dueto reduced or defective

Read More


Alliance for Regenerative Medicine: Pharmaceutical Strategy Could Save European ATMP Development

The Alliance for Regenerative Medicine (ARM) welcoming the opportunity to provide feedback on the roadmap to the EC pharmaceutical strategy has sent the following response. ARM is the leading international advocacy organisation dedicated to realizing the promise of advanced therapy medicinal products (ATMPs) and represents the interests of 350+ members worldwide and 70+ members across

Read More